JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 180 filers reported holding JUNO THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.57 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $8,468,000 | -5.4% | 185,238 | -7.2% | 0.01% | 0.0% |
| Q3 2017 | $8,952,000 | +93.6% | 199,530 | +29.0% | 0.01% | +75.0% |
| Q2 2017 | $4,623,000 | +50.5% | 154,649 | +11.7% | 0.00% | +33.3% |
| Q1 2017 | $3,071,000 | -51.0% | 138,396 | -58.3% | 0.00% | -40.0% |
| Q4 2016 | $6,263,000 | +150.5% | 332,240 | +298.7% | 0.01% | +150.0% |
| Q3 2016 | $2,500,000 | -34.3% | 83,340 | -15.9% | 0.00% | -33.3% |
| Q2 2016 | $3,808,000 | +16.7% | 99,064 | +15.6% | 0.00% | 0.0% |
| Q1 2016 | $3,263,000 | -41.1% | 85,671 | -32.0% | 0.00% | -50.0% |
| Q4 2015 | $5,539,000 | -40.0% | 125,989 | -44.5% | 0.01% | -33.3% |
| Q3 2015 | $9,230,000 | -8.3% | 226,850 | +20.2% | 0.01% | 0.0% |
| Q2 2015 | $10,063,000 | +2454.1% | 188,673 | +2802.7% | 0.01% | – |
| Q1 2015 | $394,000 | – | 6,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |